000 04296nam a2200421 i 4500
999 _c361254
_d361254
001 361254
003 ES-MaUEC
005 20230102121334.0
006 a||||fo|||| 00| 0
007 cr nn nnnaamaa
008 210610s2021 sz | o |||| 0|eng d
020 _a9783030633691
024 7 _a10.1007/978-3-030-63369-1
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRC280.C6
_b2021 EB
245 0 0 _aColon Cancer Diagnosis and Therapy :
_bVolume 1
_cedited by Ganji Purnachandra Nagaraju, Dhananjay Shukla, Naveen Kumar Vishvakarma
250 _aFirst edition 2021
264 1 _aCham
_bSpringer International Publishing
_c2021
300 _a1 recurso en línea (XII, 369 páginas)
_b20 ilustraciones a color
336 _2rdacontent
_aTexto
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _aArchivo de texto
_bPDF
490 0 _aBiomedical and Life Sciences (SpringerNature-11642)
490 0 _aBiomedical and Life Sciences (R0) (SpringerNature-43708)
505 0 _aEpidimology of colorectal cancer -- Colorectal cancer: A model for the study of cancer immunology -- Impact of Covid-19 Pandemic on Gastro Intestinal Cancer Patients: An Emphasis on Colorectal Cancer -- Potential role of NMR and MRI in colon cancer -- Role of micro-RNA in-situ hybridization in colon cancer diagnosis -- Role of epigenetics in colorectal cancer -- Exosomal biomarkers in colorectal cancer -- Biomarkers as putative therapeutic targets in colorectal cancer -- Proteins involved in colorectal cancer: Identification strategies and possible roles -- Short-chain fatty acids as therapeutic agents in colon malignancies -- Targeting of angiogenesis for colorectal cancer therapy -- Anti‐inflammatory molecular mechanism and contribution of drug transport molecules in colorectal cancer cells -- Emerging role of circulating tumour DNA in treatment response prognosis in colon cancer -- Immuno-modulating mediators of colon cancer as immunotherapeutic: mechanism and potential -- Immune checkpoint inhibitors as armor for targeted immunotherapy of colorectal cancer -- Examining the role of the MACC1 gene in colorectal cancer metastasis -- Index.
520 3 _aColorectal cancer (CRC) is a major global health challenge as the third leading cause for cancer related mortalities worldwide. Despite advances in therapeutic strategies, the five-year survival rate for CRC patients has remained the same over time due to the fact that patients are often diagnosed in advanced metastatic stages. Drug resistance is another common reason for poor prognosis. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early stage diagnosis. This book is the first of three volumes on recent developments in colorectal diagnosis and therapy. Each volume can be read on its own, or together. Each volume focuses on different novel therapeutic advances, biomarkers, and identifies therapeutic targets for treatment. Written by leading international experts in the field, coverage also addresses the role of diet habits and lifestyle in reducing gastrointestinal disorders and incidence of CRC. Chapters discuss current and future diagnostic and therapeutic options for colorectal cancer patients, focusing on immunotherapeutic, nanomedicine, biomarkers, and dietary factors for the effective management of colon cancer.
988 _aSpringer_BiomedLife_2021
650 7 _2embne
_9182269
_aColon
_xCáncer
700 1 _aNagaraju, Ganji Purnachandra.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aShukla, Dhananjay.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aVishvakarma, Naveen Kumar.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
776 0 8 _iPrinted edition:
_z9783030633684
776 0 8 _iPrinted edition:
_z9783030633707
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-63369-1
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b01/2022
_dz
_eb
_zSI